FDA approves ritlecitinib for adults and adolescents with severe alopecia areata

The U.S. Food and Drug Administration (FDA) has approved to ritlecitinib (Litfulo; Pfizer), the first FDA-approved small molecule therapy specifically designed for severe alopecia areata. The medication functions by targeting specific signaling pathways implicated in the disease’s progression.

Clinical trials conducted by Pfizer demonstrated the effectiveness and safety of ritlecitinib in addressing severe alopecia areata. Results from the trials revealed that a considerable number of participants treated with ritlecitinib demonstrated hair regrowth, surpassing the outcomes observed in the control group.

Common adverse reactions observed in clinical trials include nausea, headache, and fatigue.

Read the full press release here.